Sialylated Immunoglobulin G Can Neutralize Influenza Virus Infection Through Receptor Mimicry
Overview
Authors
Affiliations
Influenza viruses possess a great threat to human health, but there is still no effective drug to deal with the outbreak of possible new influenza subtypes. In this study, we first fractionated sialylated immunoglobulin G (IgG), mainly Fab sialylated fraction, with sambucus nigra agglutinin affinity chromatography. We then demonstrated that sialylated IgG possessed more effective neutralizing activity against 2009 A (H1N1) subtype than that of IgG mixture, and sialosides on the Fab is crucial in this neutralization reaction as when such residues were removed with neuraminidase A digestion the blocking effect was significantly reduced. It appears that sialic acid residues attached to Fab could serve as binding moieties to receptor binding site of influenza virus. These findings indicate that sialylated IgG probably is an effective anti-influenza broad-spectrum drug utilizing its receptor mimicry to competitively inhibit the attachment of influenza viruses with sialic acid receptors on target cells. This property would be particularly useful if it can be applied to prevent newly emerged influenza virus strain infections in future epidemics.
Antibody-mediated control mechanisms of viral infections.
Mackin S, Sariol A, Diamond M Immunol Rev. 2024; 328(1):205-220.
PMID: 39162394 PMC: 11661935. DOI: 10.1111/imr.13383.
Differences in Immunoglobulin G Glycosylation Between Influenza and COVID-19 Patients.
Batinjan M, Petrovic T, Vuckovic F, Hadzibegovic I, Radovani B, Jurin I Engineering (Beijing). 2022; .
PMID: 36093331 PMC: 9446557. DOI: 10.1016/j.eng.2022.08.007.
Immunoglobulin Infusion as Therapy Against Influenza?.
Huckriede A EBioMedicine. 2017; 19:10-11.
PMID: 28431940 PMC: 5440623. DOI: 10.1016/j.ebiom.2017.04.021.
Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.
Rockman S, Lowther S, Camuglia S, Vandenberg K, Taylor S, Fabri L EBioMedicine. 2017; 19:119-127.
PMID: 28408242 PMC: 5440604. DOI: 10.1016/j.ebiom.2017.04.010.